Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G12C
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
Guardant360® CDx (53)
therascreen® KRAS RGQ PCR Kit (5)
Agilent Resolution ctDx FIRST Assay (1)
Guardant360® CDx (53)
therascreen® KRAS RGQ PCR Kit (5)
Agilent Resolution ctDx FIRST Assay (1)
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
D-1553
Sensitive: C2 – Inclusion Criteria
J Thorac Oncol - 3 days (New C3)
D-1553
Sensitive
:
C2
J Thorac Oncol - 3d
D-1553
Sensitive: C2 – Inclusion Criteria
J Thorac Oncol - 3 days
D-1553
Sensitive
:
C2
J Thorac Oncol - 3 days - (New C3)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib
Sensitive: A1 - Approval
AACR 2023 - 1 week (New C3)
sotorasib
Sensitive
:
A1
AACR 2023 - 1wk
sotorasib
Sensitive: A1 - Approval
AACR 2023 - 1 week
sotorasib
Sensitive
:
A1
AACR 2023 - 1 week - (New C3)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
VS-6766
Sensitive: C2 – Inclusion Criteria
AACR 2023 - 1 week (New D)
VS-6766
Sensitive
:
C2
AACR 2023 - 1wk
VS-6766
Sensitive: C2 – Inclusion Criteria
AACR 2023 - 1 week
VS-6766
Sensitive
:
C2
AACR 2023 - 1 week - (New D)
KRAS G12C
Bladder Cancer
KRAS G12C
Bladder Cancer
adagrasib + nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
adagrasib + nanoparticle albumin-bound rapamycin
Sensitive
:
D
AACR 2023 - 1wk
adagrasib + nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
AACR 2023 - 1 week
adagrasib + nanoparticle albumin-bound rapamycin
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Bladder Cancer
KRAS G12C
Bladder Cancer
sotorasib + nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
sotorasib + nanoparticle albumin-bound rapamycin
Sensitive
:
D
AACR 2023 - 1wk
sotorasib + nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
AACR 2023 - 1 week
sotorasib + nanoparticle albumin-bound rapamycin
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
adagrasib + nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
adagrasib + nanoparticle albumin-bound rapamycin
Sensitive
:
D
AACR 2023 - 1wk
adagrasib + nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
AACR 2023 - 1 week
adagrasib + nanoparticle albumin-bound rapamycin
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib + nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
sotorasib + nanoparticle albumin-bound rapamycin
Sensitive
:
D
AACR 2023 - 1wk
sotorasib + nanoparticle albumin-bound rapamycin
Sensitive: D – Preclinical
AACR 2023 - 1 week
sotorasib + nanoparticle albumin-bound rapamycin
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Lung Cancer
KRAS G12C
Lung Cancer
KRAS G12C inhibitor
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
KRAS G12C inhibitor
Sensitive
:
D
AACR 2023 - 1wk
KRAS G12C inhibitor
Sensitive: D – Preclinical
AACR 2023 - 1 week
KRAS G12C inhibitor
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
ZG19018 + donafenib
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ZG19018 + donafenib
Sensitive
:
D
AACR 2023 - 1wk
ZG19018 + donafenib
Sensitive: D – Preclinical
AACR 2023 - 1 week
ZG19018 + donafenib
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
ZG19018
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ZG19018
Sensitive
:
D
AACR 2023 - 1wk
ZG19018
Sensitive: D – Preclinical
AACR 2023 - 1 week
ZG19018
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Pancreatic Cancer
KRAS G12C
Pancreatic Cancer
ZG19018
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ZG19018
Sensitive
:
D
AACR 2023 - 1wk
ZG19018
Sensitive: D – Preclinical
AACR 2023 - 1 week
ZG19018
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
ZG19018
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ZG19018
Sensitive
:
D
AACR 2023 - 1wk
ZG19018
Sensitive: D – Preclinical
AACR 2023 - 1 week
ZG19018
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
tipifarnib
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
tipifarnib
Sensitive
:
D
AACR 2023 - 1wk
tipifarnib
Sensitive: D – Preclinical
AACR 2023 - 1 week
tipifarnib
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib + VIC-1911
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
sotorasib + VIC-1911
Sensitive
:
D
AACR 2023 - 1wk
sotorasib + VIC-1911
Sensitive: D – Preclinical
AACR 2023 - 1 week
sotorasib + VIC-1911
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
sotorasib + JSI-1187
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
sotorasib + JSI-1187
Sensitive
:
D
AACR 2023 - 1wk
sotorasib + JSI-1187
Sensitive: D – Preclinical
AACR 2023 - 1 week
sotorasib + JSI-1187
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Solid Tumor
KRAS G12C
Solid Tumor
TEB-17231
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
TEB-17231
Sensitive
:
D
AACR 2023 - 1wk
TEB-17231
Sensitive: D – Preclinical
AACR 2023 - 1 week
TEB-17231
Sensitive
:
D
AACR 2023 - 1 week - (New D)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
adagrasib
Sensitive: A1 - Approval
adagrasib
Sensitive
:
A1
adagrasib
Sensitive: A1 - Approval
adagrasib
Sensitive
:
A1
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
KRAS G12C
Lung Non-Squamous Non-Small Cell Cancer
KRAS G12C
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
abemaciclib
Sensitive: B - Late Trials
abemaciclib
Sensitive
:
B
abemaciclib
Sensitive: B - Late Trials
abemaciclib
Sensitive
:
B
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
cetuximab + adagrasib
Sensitive: B - Late Trials
cetuximab + adagrasib
Sensitive
:
B
cetuximab + adagrasib
Sensitive: B - Late Trials
cetuximab + adagrasib
Sensitive
:
B
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
panitumumab
Resistant: B - Late Trials
panitumumab
Resistant
:
B
panitumumab
Resistant: B - Late Trials
panitumumab
Resistant
:
B
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib + BBP-398
Sensitive: B - Late Trials
sotorasib + BBP-398
Sensitive
:
B
sotorasib + BBP-398
Sensitive: B - Late Trials
sotorasib + BBP-398
Sensitive
:
B
KRAS G12C
Ampulla of Vater Carcinoma
KRAS G12C
Ampulla of Vater Carcinoma
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Pancreatic Cancer
KRAS G12C
Pancreatic Cancer
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Cholangiocarcinoma
KRAS G12C
Cholangiocarcinoma
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Ovarian Cancer
KRAS G12C
Ovarian Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Pancreatic Cancer
KRAS G12C
Pancreatic Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Endometrial Cancer
KRAS G12C
Endometrial Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Melanoma
KRAS G12C
Melanoma
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Endometrial Cancer
KRAS G12C
Endometrial Cancer
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Gastrointestinal Cancer
KRAS G12C
Gastrointestinal Cancer
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Gastrointestinal Cancer
KRAS G12C
Gastrointestinal Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Pancreatic Ductal Adenocarcinoma
KRAS G12C
Pancreatic Ductal Adenocarcinoma
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Lung Cancer
KRAS G12C
Lung Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Solid Tumor
KRAS G12C
Solid Tumor
D-1553
Sensitive: C2 – Inclusion Criteria
D-1553
Sensitive
:
C2
D-1553
Sensitive: C2 – Inclusion Criteria
D-1553
Sensitive
:
C2
KRAS G12C
Lung Cancer
KRAS G12C
Lung Cancer
D-1553
Sensitive: C2 – Inclusion Criteria
D-1553
Sensitive
:
C2
D-1553
Sensitive: C2 – Inclusion Criteria
D-1553
Sensitive
:
C2
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
MEK inhibitor + sotorasib
Sensitive: C2 – Inclusion Criteria
MEK inhibitor + sotorasib
Sensitive
:
C2
MEK inhibitor + sotorasib
Sensitive: C2 – Inclusion Criteria
MEK inhibitor + sotorasib
Sensitive
:
C2
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
RMC-4630
Sensitive: C2 – Inclusion Criteria
RMC-4630
Sensitive
:
C2
RMC-4630
Sensitive: C2 – Inclusion Criteria
RMC-4630
Sensitive
:
C2
KRAS G12C
Solid Tumor
KRAS G12C
Solid Tumor
GFH925
Sensitive: C2 – Inclusion Criteria
GFH925
Sensitive
:
C2
GFH925
Sensitive: C2 – Inclusion Criteria
GFH925
Sensitive
:
C2
KRAS G12C
Solid Tumor
KRAS G12C
Solid Tumor
JAB-21822
Sensitive: C2 – Inclusion Criteria
JAB-21822
Sensitive
:
C2
JAB-21822
Sensitive: C2 – Inclusion Criteria
JAB-21822
Sensitive
:
C2
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
RG6330
Sensitive: C2 – Inclusion Criteria
RG6330
Sensitive
:
C2
RG6330
Sensitive: C2 – Inclusion Criteria
RG6330
Sensitive
:
C2
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
RG6330
Sensitive: C2 – Inclusion Criteria
RG6330
Sensitive
:
C2
RG6330
Sensitive: C2 – Inclusion Criteria
RG6330
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login